Travere Therapeutics' Consolidated Net Income rose 25806.00% to $25.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$28.3 million, marking a year-over-year decrease of 1014.35%. This contributed to the annual value of -$915,000 for FY2024, which is 100.35% down from last year.
As of Q3 2025, Travere Therapeutics' Consolidated Net Income stood at $25.7 million, which was up 301.54% from -$12.8 million recorded in Q2 2025.
In the past 5 years, Travere Therapeutics' Consolidated Net Income registered a high of $240.0 million during Q3 2023, and its lowest value of -$88.8 million during Q4 2021.
In the last 3 years, Travere Therapeutics' Consolidated Net Income had a median value of -$100,000 in 2024 and averaged $21.4 million.
Over the last 5 years, Travere Therapeutics' Consolidated Net Income had its largest YoY gain of 25,806.00% in 2025, and its largest YoY loss of 39,925.24% in 2025.
Travere Therapeutics' Consolidated Net Income (Quarterly) stood at -$88.8 million in 2021, then spiked by 122.32% to $19.8 million in 2022, then crashed by 107.96% to -$1.6 million in 2023, then skyrocketed by 100.25% to $4,000 in 2024, then soared by 25,806.00% to $25.7 million in 2025.
Its last three reported values are $25.7 million in Q3 2025, -$12.8 million for Q2 2025, and -$41.2 million during Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value